Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lopinavir/ritonavir monotherapy in HIV-infected children
NCT00626301Phase 4Completed
- Sponsor
- HIV-NAT
- Start
- Nov 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV), sponsored by HIV-NAT. Primary endpoints: Virological outcome at 48 weeks, Immunological outcome at 48 weeks and 1 more. Started Nov 2007; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00626301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626301.